staurosporine has been researched along with dorsomorphin in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daniels, RN; Gentry, PR; Hao, J; Ho, JN; Hong, CC; Hopkins, CR; Karim, KA; Lewis, JA; Lindsley, CW | 1 |
| Anderson, E; Boardman, PE; Bryk, R; Chao, P; Cole, JL; Conn, GL; Duffy, NP; Griffin, JH; Nathan, C; Raimundo, BC; Wu, K | 1 |
| Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A | 1 |
| Jin, CH; Kim, DK; Krishnaiah, M; Lee, HJ; Lee, K; Park, HJ; Park, SJ; Rao, KS; Sheen, YY; Sreenu, D; Subrahmanyam, VB | 1 |
4 other study(ies) available for staurosporine and dorsomorphin
| Article | Year |
|---|---|
In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors.
Topics: Animals; Bone Morphogenetic Proteins; Drug Evaluation, Preclinical; Embryo, Nonmammalian; Pyrazoles; Pyrimidines; Quinolines; Structure-Activity Relationship; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Zebrafish | 2010 |
Identification of new inhibitors of protein kinase R guided by statistical modeling.
Topics: Animals; Computer Simulation; Dose-Response Relationship, Drug; eIF-2 Kinase; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Macrophages; Mice; Models, Statistical; Molecular Structure; Small Molecule Libraries | 2011 |
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase | 2013 |
Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/
Topics: Administration, Oral; Aniline Compounds; Animals; Antifibrinolytic Agents; Antineoplastic Agents; Biological Availability; Drug Discovery; HEK293 Cells; Humans; Immunotherapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Rats; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Structure-Activity Relationship; Triazoles | 2014 |